Renaissance Technologies LLC Invests $34,000 in Bullfrog AI Holdings, Inc. (NASDAQ:BFRG)

Renaissance Technologies LLC purchased a new position in shares of Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 19,800 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned 0.25% of Bullfrog AI as of its most recent SEC filing.

Separately, Fortem Financial Group LLC purchased a new stake in shares of Bullfrog AI in the first quarter valued at approximately $171,000. Hedge funds and other institutional investors own 0.96% of the company’s stock.

Bullfrog AI Stock Performance

BFRG opened at $2.64 on Tuesday. The business’s fifty day moving average is $2.58 and its two-hundred day moving average is $2.65. The company has a market cap of $20.73 million, a price-to-earnings ratio of -3.00 and a beta of -0.21. Bullfrog AI Holdings, Inc. has a one year low of $1.43 and a one year high of $8.35.

Bullfrog AI (NASDAQ:BFRG) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In other Bullfrog AI news, CEO Vininder Singh sold 14,405 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $2.65, for a total value of $38,173.25. Following the transaction, the chief executive officer now owns 2,478,041 shares in the company, valued at $6,566,808.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 31,603 shares of company stock valued at $82,989 in the last quarter. Company insiders own 33.90% of the company’s stock.

About Bullfrog AI

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.